Serum Regucalcin Level and Chronic Hepatitis B
Study Details
Study Description
Brief Summary
This study, it was aimed to investigate the relationship between serum regucalcin level and liver fibrosis level in patients with CHB infection.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Chronic hepatitis B (CHB) infection continues to be an important health problem due to its high morbidity and mortality. For this reason, it is very important to determine the appropriate timing to start antiviral therapy in patients with CHB infection and to evaluate the stage of liver fibrosis in the treatment follow-up. Liver biopsy is the gold standard for detecting liver fibrosis. Although it is generally accepted to be a safe procedure, it can cause some serious complications. For this reason, in recent years, many studies have been conducted on new noninvasive tests in the evaluation of liver fibrosis. One of them is the serum regucalcin level. Studies have shown that serum regucalcin levels increase in liver damage, but there is no study in the literature comparing liver fibrosis and serum regucalcin levels in CHB infection. This study, it was aimed to investigate the relationship between serum regucalcin level and liver fibrosis level in patients with CHB infection.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Chronic Hepatitis B Measurement of serum regucalcin level |
Diagnostic Test: Serum regucalcin level
During routine outpatient controls, serum regucalcin level will be measured from the rest of the blood taken for examinations.
|
| Other: Healthy Volunteers Measurement of serum regucalcin level |
Diagnostic Test: Serum regucalcin level
During routine outpatient controls, serum regucalcin level will be measured from the rest of the blood taken for examinations.
|
Outcome Measures
Primary Outcome Measures
- Comparison of serum regucalcin levels with liver fibrosis levels [Performing liver biopsies: 3 months, data collection: 1 month, writing the article: 1 month]
We grouped chronic hepatitis b patients as mild fibrosis (stage 1-2) and moderate fibrosis (stage 3-4) according to the fibrosis stage at liver biopsy stage. We selected healthy volunteers without liver disease as the control group. We will measure the serum regucalcin level in these 3 groups and make a comparison between the groups. We want to show the relationship between serum regucalcin level and fibrosis level in chronic hepatitis b.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Being followed up with a diagnosis of chronic hepatitis B
-
Not having a known history of liver disease who applied to our outpatient clinic for other reasons
-
Having a liver biopsy
-
≥18 years
Exclusion Criteria:
- <18 years
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Konya Training and Research Hospital | Konya | Turkey | 42090 |
Sponsors and Collaborators
- Konya Meram State Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- Wei X, Yu H, Zhao P, Xie L, Li L, Zhang J. Serum regucalcin is a useful indicator of liver injury severity in patients with hepatitis B virus-related liver diseases. Braz J Med Biol Res. 2019 Sep 30;52(10):e8845. doi: 10.1590/1414-431X20198845. eCollection 2019.
- Yamaguchi M, Isogai M, Shimada N. Potential sensitivity of hepatic specific protein regucalcin as a marker of chronic liver injury. Mol Cell Biochem. 1997 Feb;167(1-2):187-90.
- 10542